Investigation of Pazopanib and Human Serum Albumin Interaction Using Spectroscopic and Molecular Docking Approaches

Pazopanib (PAZ), a tyrosine kinase inhibitor, is used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). The FDA approved PAZ for RCC in 2009 and for STS in 2012. The antitumor activity of pazopanib, according to the degree of inhibition, shows different results dep...

Full description

Bibliographic Details
Main Authors: Ahmet Cetinkaya, Mehmet Gokhan Caglayan, Mehmet Altay Unal, Pinar Beyazkilic, Caglar Elbuken, Esen Bellur Atici, Sibel A. Ozkan
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Analytica
Subjects:
Online Access:https://www.mdpi.com/2673-4532/3/1/11